Microglial activation and dopamine terminal loss in early Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Microglial activation and dopamine terminal loss in early Parkinson's disease.

Microglial activation and dopamine terminal loss in early Parkinson's disease.

http://www.wikidata.org/entity/Q45237159

about

Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System Current status of biomarker research in neurology TSPO imaging in parkinsonian disorders Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's Disease Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies Glia and alpha-synuclein in neurodegeneration: A complex interaction M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity Olfactory Sensory Activity Modulates Microglial-Neuronal Interactions during Dopaminergic Cell Loss in the Olfactory Bulb Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?Estrogen ameliorates microglial activation by inhibiting the Kir2.1 inward-rectifier K(+) channel.Neuroimaging biomarkers of neurodegenerative diseases and dementia Protective Microglia and Their Regulation in Parkinson's Disease What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Parkinson's disease as a result of aging Imaging neuroinflammation in multiple sclerosis using TSPO-PET In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's disease Pesticides, microglial NOX2, and Parkinson's disease Striatal neuroinflammation promotes Parkinsonism in rats Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state.The role of biomarkers and imaging in Parkinson's disease.Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.TSPO activation modulates the effects of high pressure in a rat ex vivo glaucoma model.Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.Prospect of cell therapy for Parkinson's disease.

P2860

Q22241651-787B83E3-9752-4A39-BE86-B209D71C8DBE Q24641816-42BE93AD-FBB5-4B08-A52F-4AD914821248 Q24644752-C0BF10EC-52B0-4341-9C69-463275FEAB2A Q26738336-5AABF3FB-61ED-49AB-B108-1CA6B487BF56 Q26744505-F253EAD0-23BF-461E-A78C-761863221AB1 Q26747214-23BB7D94-52BE-4A48-830D-3F95A7BBF569 Q26747508-7B97F04F-E549-4A68-BEBF-B5AC8C819FF6 Q26748711-3E822A51-19EC-4286-A80C-0353B6B7AB29 Q26748974-30FFA282-5A96-4160-A8B9-93467AC29806 Q26750370-D1CBDE03-FD71-4DAE-B68D-782DC7ECE307 Q26767289-8A845828-6B23-4B71-80CD-D88C5FACDAF6 Q26779933-D59461C5-2B53-4E23-B796-33B3C0D7B814 Q26795984-F5BE8721-9FB0-4452-A815-B5761B562712 Q26851153-F70DBB50-C2F0-4BE7-883A-1B702DA269D2 Q27024667-2A6822DE-ACC3-46B5-8076-F7A73FEC5480 Q27027973-30BF8EC1-5E0B-435C-9CC6-0FD93FE61057 Q27319585-E38783B0-AF81-494D-9578-8FAE6D3C3CD1 Q27324133-5B0EA4D8-BE48-4B51-B336-99F8F1B76286 Q27333476-22218A89-A4E9-4208-9A0A-55585D2910B2 Q27691820-0F3613EF-F743-403E-BAF6-E0D5C8CBAF23 Q28079731-36B5051E-9273-4A0A-B8C1-A678E1239F5B Q28083203-8B607BC6-5221-4906-9BCA-F17BA796CC95 Q28084395-6A196471-50DB-4F4D-A007-58A461939F55 Q28084625-5A0B5404-DC3F-4E8A-A5A9-5A8E5C5B1B10 Q28274003-10F49F73-C488-404D-8D40-6A1C650BF8CF Q28397585-BE00B4F1-9703-45A2-98A1-E3D0327C176E Q28475466-65A239F9-9710-456F-A716-18189E519255 Q28482356-ED027C84-C39B-4208-9FD6-F260D5ABD052 Q28508394-D1C89690-DCA5-45FA-B591-37DCAF7337B6 Q30649552-D10FB038-3E89-4756-9FAB-23E8B4EE1958 Q31041660-79CDE976-FC3C-4B04-B81D-5DA775B84E3A Q31158920-0E7E34B9-504E-489A-83E4-D89E99C4FC36 Q33526342-F671CE39-B4A3-478C-8D6F-3A744A38C354 Q33624586-A7829C50-6BAF-4788-96EC-B5D6CB62BE68 Q33627982-0A42FDFA-4BA5-44A2-AF50-EA16B1247A04 Q33807216-87760053-0F6D-4175-A5B4-06AB6D07A5D5 Q33836942-8F6B7F5A-64CD-4BA2-B3F8-01351A6C8F7E Q34014053-E19549BF-B729-4784-982F-B2B95616AAEE Q34077007-98941DDC-5367-4DBC-AFF4-62FDB92A54D7 Q34131282-79B83448-BD3C-498A-99E4-5984FC284259

P2860

Microglial activation and dopamine terminal loss in early Parkinson's disease.

http://www.wikidata.org/entity/Q45237159

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@en

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@nl

type

label

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@en

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@nl

prefLabel

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@en

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@nl

P1433

Q45237159-5ACE23B8-3C0F-4762-8F6C-AC0E246B3A8C

P1476

Q45237159-2026C0BF-0E84-49ED-8DD9-AAAE75EEFC86

P2093

Q45237159-2E0A36CE-F318-4AC1-9C43-C1B55831D0F3

Q45237159-430E8452-BB85-4818-BF15-20554E2FA38E

Q45237159-55679CE9-5D1B-45C7-BCC5-2A280F854CAC

Q45237159-5BBEF23F-9049-4C2E-AA46-6504BF43EA1E

Q45237159-9A3C9516-5225-4919-8098-DBF9884091A3

Q45237159-AF15C748-0ACD-4F4C-9FD3-DD6F2CBCC55F

Q45237159-BD473EC0-871B-4A7F-AA40-3A20087F8373

P2860

Q45237159-034F08C2-9DDD-4C50-A902-28DF2842EDE1

Q45237159-56BF2139-6776-4D6D-A2FE-9007DD549A74

P304

Q45237159-7329CAF8-E725-4650-BF98-F722B65894CD

P31

Q45237159-D07372A2-E176-44C4-BA59-FA62EED4772E

P356

Q45237159-064CA79B-2D83-4E1A-B144-DDBCF905C00F

P433

Q45237159-D22A5D5E-CB0B-4B96-A6D3-BA1BFCC43B79

P478

Q45237159-270F8080-F8C5-4E70-B8A5-175DBFAB0789

P577

Q45237159-25032CAD-768C-4E5F-B62A-E571815627AC

P698

Q45237159-E1A609E2-1321-4419-8950-AB5DDC370C70

P921

Q45237159-96CDBFC5-BFCB-47F2-AF66-8DBA29776FB9

Q45237159-B8E9C063-C2F9-42B4-906B-235DE8B1E0A0

Q45237159-ab17dc00-710a-48c4-84fd-77ba04133e6b

P356

P1433

Annals of Neurology

P1476

Microglial activation and dopamine terminal loss in early Parkinson's disease.

@en

P2093

Etsuji Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Masami Futatsubashi

http://www.w3.org/2001/XMLSchema#string

Tatsuo Torizuka

http://www.w3.org/2001/XMLSchema#string

Tomomi Ogusu

http://www.w3.org/2001/XMLSchema#string

Toshihiko Kanno

http://www.w3.org/2001/XMLSchema#string

Yasuomi Ouchi

http://www.w3.org/2001/XMLSchema#string

Yoshimoto Sekine

http://www.w3.org/2001/XMLSchema#string

P2860

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies.

P304

168-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.20338

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15668962

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease